Healthcare & Life Sciences
Coltac Therapeutics
Israel
About
Coltac Therapeutics develops molecular glue drug candidates for targeted protein degradation in cancer by using a proprietary high-throughput E. coli-based positive selection screening system combined with structural biology and computational approaches to select specific E3 ligase libraries.
Explore Coltac Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.